• Atossa outlined a plan to staple one contingent value right to each ATOS share, tied to monetizing its first qualifying FDA priority review voucher.
• The CVR would transfer with the common stock, would not trade separately, would not be registered, would not have its own CUSIP.
• Holders would receive 25% of net monetization proceeds, capped at USD 50 million in aggregate, if a qualifying voucher is obtained.
• No priority review voucher has been awarded; the CVRs would expire Dec. 31, 2036 unless extended.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-406036), on September 29, 2026, and is solely responsible for the information contained therein.